| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1370987 | Bioorganic & Medicinal Chemistry Letters | 2011 | 6 Pages |
Abstract
The discovery of novel and highly potent oxopiperazine based B1 receptor antagonists is described. Compared to the previously described arylsulfonylated (R)-3-amino-3-phenylpropionic acid series, the current compounds showed improved in vitro potency and metabolic stability. Compound 17, 2-((2R)-1-((4-methylphenyl)sulfonyl)-3-oxo-2-piperazinyl)-N-((1R)-6-(1-piperidinylmethyl)-1,2,3,4-tetrahydro-1-naphthalenyl)acetamide, showed EC50 of 10.3 nM in a rabbit biochemical challenge model. The practical syntheses of chiral arylsulfonylated oxopiperazine acetic acids are also described.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Jian Jeffrey Chen, Thomas Nguyen, Derin C. D’Amico, Wenyuan Qian, Jason Human, Toshihiro Aya, Kaustav Biswas, Christopher Fotsch, Nianhe Han, Qingyian Liu, Nobuko Nishimura, Tanya A.N. Peterkin, Kevin Yang, Jiawang Zhu, Babak Bobby Riahi,